Clinical trials
Overweight trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
301 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 4 |
| 2012 | 4 |
| 2014 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 9 |
| 2021 | 15 |
| 2022 | 19 |
| 2023 | 32 |
| 2024 | 50 |
| 2025 | 61 |
| 2026 | 82 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 131 |
| Recruiting | 75 |
| Not yet recruiting | 34 |
| Active, not recruiting | 34 |
| Unknown status | 21 |
| Withdrawn | 4 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 22 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 11 |
| Novo Nordisk A/S | 11 |
| Shanghai Minwei Biotechnology Co., Ltd | 11 |
| Beijing QL Biopharmaceutical Co.,Ltd | 8 |
| Innovent Biologics (Suzhou) Co. Ltd. | 7 |
| Vincentage Pharma Co., Ltd | 7 |
| AstraZeneca | 6 |
| BrightGene Bio-Medical Technology Co., Ltd. | 6 |
| Gan & Lee Pharmaceuticals. | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Overweight | 301 |
| Obesity | 279 |
| Diabetes Mellitus, Type 2 | 35 |
| Weight Loss | 11 |
| Metabolic Syndrome | 10 |
| Diabetes Mellitus | 7 |
| Prediabetic State | 7 |
| Hypertension | 5 |
| Polycystic Ovary Syndrome | 5 |
| Body Weight | 4 |
Trials
Showing 51 to 75 of 301. Each trial links to its page on Pharma Observatory.
201 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.